Somatostatin Receptor-positive Neuroendocrine Tumor
2 clinical trials · Condition
◉ Watch Somatostatin Receptor-positive Neuroendocrine Tumor
| Record | Firm | Date |
|---|---|---|
| LUTATHERA Injection General Use Result Survey (NCT05844332) | Novartis Pharmaceuticals | 2021-12-17 |
Track Somatostatin Receptor-positive Neuroendocrine Tumor automatically
Every clearance here is in the API, with alerts when new ones post.